• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics Inc (NQ: DYN )

    44.25 +1.06 (+2.45%)
    Streaming Delayed Price Updated: 3:26 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Dyne Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
    Via Benzinga
    Chart Of The Day: Dyne Therapeutics - Deeply Discounted
    Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United... 
    Via Talk Markets
    Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
    U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    The 3 Most Undervalued Biotech Stocks to Buy in June 2024
    https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
    Via InvestorPlace
    Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Announces Proposed Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Why Is Dyne Therapeutics Stock Soaring On Monday?
    Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle... 
    Via Benzinga
    Tech Surge Boosts Nasdaq To Record Highs
    The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
    Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD. 
    Via Investor's Business Daily
    Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday! 
    Via InvestorPlace
    Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
    DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
    Via Benzinga
    Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
    U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Dyne Therapeutics Announces CEO Transition
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
    Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven... 
    Via Benzinga
    Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
    Via Benzinga
    Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.